Ovestin Leggangakrem 1 mg/g Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

ovestin leggangakrem 1 mg/g

aspen pharma trading limited - estriolum inn - leggangakrem - 1 mg/g

Ovestin Leggangastíll 0,5 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

ovestin leggangastíll 0,5 mg

aspen pharma trading limited - estriolum inn - leggangastíll - 0,5 mg

Ovestin Tafla 1 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

ovestin tafla 1 mg

aspen pharma trading limited - estriolum inn - tafla - 1 mg

Ovestin Tafla 2 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

ovestin tafla 2 mg

aspen pharma trading limited - estriolum inn - tafla - 2 mg

Tamsulosin Viatris (Tamsulosin Mylan 0,4 mg hart hylki með breyttan losunarhraða) Hart hylki með breyttan losunarhraða 0,4 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

tamsulosin viatris (tamsulosin mylan 0,4 mg hart hylki með breyttan losunarhraða) hart hylki með breyttan losunarhraða 0,4 mg

viatris limited - tamsulosinum hýdróklóríð - hart hylki með breyttan losunarhraða - 0,4 mg

ZESUVA (Sunitinib Alvogen) Hart hylki 12,5 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

zesuva (sunitinib alvogen) hart hylki 12,5 mg

zentiva k.s.* - sunitinibum inn - hart hylki - 12,5 mg

ZESUVA (Sunitinib Alvogen) Hart hylki 25 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

zesuva (sunitinib alvogen) hart hylki 25 mg

zentiva k.s.* - sunitinibum inn - hart hylki - 25 mg

ZESUVA (Sunitinib Alvogen) Hart hylki 50 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

zesuva (sunitinib alvogen) hart hylki 50 mg

zentiva k.s.* - sunitinibum inn - hart hylki - 50 mg

Pylclari Euroopan unioni - islanti - EMA (European Medicines Agency)

pylclari

curium pet france - piflufolastat (18f) - blöðruhálskirtli - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Soltamcin Tafla með breyttan losunarhraða 6 mg/0,4 mg Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

soltamcin tafla með breyttan losunarhraða 6 mg/0,4 mg

williams & halls ehf. - solifenacinum súkkínat; tamsulosinum hýdróklóríð - tafla með breyttan losunarhraða - 6 mg/0,4 mg